VICTORIA, April 11, 2019 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC
PINK: IPATF) announces that it has appointed Andy Nixon, Vice President of Biotherapeutics
Molecule Discovery at Boehringer Ingelheim, as a member of its
board of directors.
Dr. Nixon is a pharma executive with 20 years of industry
experience and a proven track record of leading cross-functional
teams to solve complex problems. He possesses deep domain expertise
in biologic drug discovery and non-clinical development and led the
research team that developed Dyax's pipeline therapeutic candidates
that resulted in Shire's acquisition of Dyax in 2016 for
$5.9B.
"As IPA advances its strategy for accelerated growth in the
custom therapeutic antibody space, and for sustainable shareholder
value creation, Dr. Nixon brings a unique depth of experience and
expertise that is directly relevant to IPA", said Jennifer Bath, IPA's CEO and President.
"We are pleased to have Dr. Nixon support IPA through the next
phase of our development. He is highly accomplished and has a
strong record in successfully navigating today's rapidly changing
technological environment."
With the addition of Dr. Nixon, the full IPA board will comprise
seven members, six of which are independent directors. The
continued refreshment of the board augments its diversity and
experience and adds new perspectives in the different areas
relevant to IPA.
About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal
of the research-driven pharmaceutical company Boehringer Ingelheim.
The focus in doing so is on diseases for which no satisfactory
treatment option exists to date. The company therefore concentrates
on developing innovative therapies that can extend patients' lives.
In animal health, Boehringer Ingelheim stands for advanced
prevention.
Family-owned since it was established in 1885, Boehringer
Ingelheim is one of the pharmaceutical industry's top 20 companies.
Some 50,000 employees create value through innovation daily for the
three business areas human pharmaceuticals, animal health and
biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net
sales of nearly 18.1 billion euros.
R&D expenditure, exceeding three billion
euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in
generations and focuses on long-term success. The company therefore
aims at organic growth from its own resources with simultaneous
openness to partnerships and strategic alliances in research. In
everything it does, Boehringer Ingelheim naturally adopts
responsibility towards mankind and the environment.
More information about Boehringer Ingelheim can be found
on www.boehringer-ingelheim.com or in our annual report:
http://annualreport.boehringer-ingelheim.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located at the Vancouver Island Technology Park
in Victoria, British
Columbia, in collaboration with its wholly-owned subsidiary
operations at U-Protein Express B.V., in the Life Science
Incubator, Utrecht, and ModiQuest Research, Oss, both
in the Netherlands. The
Company operates globally to offer antibody services from target
analysis to pre-clinical studies.
The services offered to clients include antibody discovery
against a broad spectrum of antigens, including challenging
targets. Amongst these services, the Company offers hybridoma
production, B-cell services, and a variety of phage display
platforms. The Company also provides a broad range of supporting
services including immunologically-based assays, recombinant
protein manufacturing, humanization, optimization, stable cell line
development, and advanced solutions to challenges faced by clients
in antibody-related research and development. The antibodies
produced by ImmunoPrecise target a wide variety of therapeutic,
diagnostic and research applications.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.